Oncolytic Virus Therapy Market Analysis & Forecast: 2025-2032

Oncolytic Virus Therapy Market

Oncolytic Virus Therapy Market is estimated to be valued at USD 17.8 Mn in 2025 and is expected to reach USD 87.3 Mn in 2032, exhibiting a compound annual growth rate (CAGR) of25.5% from 2025 to 2032.

Key Takeaways

• Based on Product Type, the Herpes Simplex Virus segment leads the market, holding an estimated share of 38.0% in 2025, due to its unique biological and therapeutic characteristics that make it particularly suitable for cancer treatment.
• Based on Application, the Melanoma segment leads the market with the largest share of the market in 2025, as this type of cancer is highly responsive to immune-based treatments.
• Based on Development Stage, the Pipeline Phase, particularly phase I segment leads the market holding a highest share in 2025, driven by the high volume of candidates, need for regulatory validation, and strategic investment.
• Based on Distribution Channel, the Hospital Pharmacies segment leads the market holding the greatest share in 2025, due to specialized handling and storage.
• Based on Region, North America is estimated to lead the market with a share of 33.50% in 2025. While, Asia Pacific, holding a share of 16.8% in 2025, is projected to be the fastest growing region.

Market Overview

Oncolytic virus therapy market is gaining momentum as a next-generation cancer treatment, harnessing genetically engineered viruses to selectively infect, replicate within, and destroy cancer cells while sparing healthy tissues. This approach offers a dual mechanism, direct tumor cell lysis and immune system activation, making it particularly effective for hard-to-treat cancers such as melanoma, lung, breast, and pancreatic cancers. The growing oncolytic virus therapy market demand is being propelled by rapid advancements in viral vector engineering, deeper insights into tumor microenvironments, and increasingly positive clinical trial results.

Current Events and their Impact on the Oncolytic Virus Therapy Market

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

End-User Feedback and Unmet Needs in the Oncolytic Virus Therapy Market

End-User Feedback

• Clinical Evidence and Efficacy: There is a consistent demand for more robust clinical data demonstrating long-term efficacy across a broader range of solid tumors. Users have noted that current clinical trials are often limited in scope, sample size, or tumor specificity.
• Safety and Tolerability: Although generally well-tolerated, some patients experience flu-like symptoms, inflammation, or localized injection site reactions. End users seek therapies with improved safety profiles, especially for patients with compromised immune systems.
• Ease of Administration: Intratumoral delivery, a common method of OV administration, presents logistical challenges in clinical practice, particularly for deep-seated or inaccessible tumors. There is a strong preference for systemically deliverable OVs that maintain tumor selectivity.
• Combination Regimens: Many practitioners are exploring OV therapies in combination with immune checkpoint inhibitors or standard chemotherapy. However, limited regulatory guidance and data on optimal dosing and sequencing remain significant barriers.

Unmet Needs

• Expanded Indications and Tumor Types: There remains a significant unmet need for effective OV therapies targeting a wider array of malignancies, especially hematologic cancers and rare tumor types.
• Predictive Biomarkers: The lack of validated biomarkers to predict patient response to OV therapy hinders personalized treatment strategies and trial design optimization.
• Regulatory and Reimbursement Pathways: Given the novel nature of OV therapies, reimbursement uncertainty and complex regulatory requirements pose challenges for adoption and market access.
• Awareness and Education: There is a need for broader education among healthcare professionals regarding OV mechanisms, clinical application, and differentiation from traditional virotherapies or immunotherapies.

Pricing Analysis of Oncolytic Virus Therapy

As of the latest available data, the OV therapy with broad market approval is Talimogene laherparepvec (T-VEC, marketed as Imlygic by Amgen), primarily indicated for the treatment of unresectable melanoma. The list price for Imlygic in the U.S. is approximately USD 65,000 to USD 80,000 per treatment course, depending on dosage and duration, though actual pricing may vary based on insurance coverage, negotiated discounts, and country-specific healthcare systems.

Segmental Insights

To learn more about this report, Download Free Sample

Oncolytic Virus Therapy Market Insights, By Product Type

Herpes Simplex Virus Holds the Dominant share on account of its Unique Biological and Therapeutic Characteristics

In terms of product type, the herpes simplex virus segment dominates the global oncolytic virus therapy market, holding an estimated share of 38.0% share in 2025, due to its unique biological and therapeutic characteristics that make it particularly suitable for cancer treatment. Herpes simplex virus has a large double-stranded DNA genome, allowing researchers to insert or delete genes to enhance tumor selectivity and immune response. Its genome can accommodate large transgenes, enabling the delivery of therapeutic payloads such as immune-stimulatory proteins (e.g., GM-CSF). HSV-based therapies not only kill cancer cells directly but also release tumor antigens that stimulate an anti-tumor immune response, effectively turning the tumor into a self-vaccine. Companies like Amgen, Replimune, and OncoVex continue to invest in HSV-based therapies for various cancers, including breast, head and neck, and pancreatic cancer. Numerous HSV-derived candidates are in Phase I to III clinical trials, expanding their relevance in the oncolytic virus therapy market.

In June 2024, Researchers at the Leibniz Institute of Virology (LIV), alongside international collaborators, visualized how herpesviruses exit the cell nucleus without damaging their envelope, which is a critical step for viral assembly and propagation. Using cutting-edge electron cryo‑tomography, the team mapped the flexible nuclear egress complex (NEC) of Herpes simplex virus 1 and a model pseudorabies virus in unprecedented detail. This was published in Nature Microbiology, and the findings offer a novel target for antiviral drug development. By disrupting NEC structural flexibility, future therapies may more effectively hinder herpesvirus replication, improving outcomes, especially for immunocompromised patients.

Oncolytic Virus Therapy Market Insights, By Application

Melanoma Acquires the Largest Share as they are Highly Responsive to Immune-Based Treatments

In terms of application, the melanoma segment is expected to command the largest share of the market in 2025. Oncolytic virus therapy is widely used in melanoma, as this type of cancer is highly responsive to immune-based treatments and presents several biological characteristics that make it an ideal target. Melanoma cells typically have a high number of genetic mutations, making them more recognizable to the immune system. Oncolytic viruses can infect and kill these cells, while also exposing tumor antigens that help the immune system mount a stronger, more targeted response.

Additionally, Numerous studies are exploring combinations of oncolytic virus therapy with other treatments like immune checkpoint inhibitors, especially in melanoma. Trials like MASTERKEY-265 (T-VEC + pembrolizumab) show promise in treating unresectable melanoma, reinforcing its central role in this field.

In December 2024, new data reveal that RP1 (vusolimogene oderparepvec), a genetically engineered HSV‑1 oncolytic virus, paired with nivolumab, achieved a 33% response rate in advanced melanoma patients previously treated with anti–PD‑1 therapy (NCT03767348). Notably, injections into deep visceral tumors such as liver and lung, proved safe and boosted responses to 42.9%, compared to 29.8% with skin-only injections. This is further proliferating the oncolytic virus therapy market share.

Oncolytic Virus Therapy Market Insights, By Development Stage

Pipeline Phase Holds the Most Prominent Share

In terms of development stage, the pipeline phase, especially the phase I segment is expected to contribute the highest share of the market in 2025, the high volume of candidates, need for regulatory validation, and strategic investment focus make Phase I the most active and in-demand development stage in the current oncolytic virus therapy landscape. The field of oncolytic virotherapy is rapidly evolving, with a surge in new viral platforms such as herpes simplex virus (HSV), adenovirus, reovirus, and vaccinia. Many of these therapies are entering Phase I for the first time, as research labs and biotech firms validate their safety in human patients.

Since oncolytic viruses are live biological agents, regulatory agencies require extensive Phase I testing to assess their safety, dosing, and immune response. This makes early-stage trials essential and highly prioritized before advancing to efficacy-focused trials.

Additionally, Major partnerships between biotech startups, universities, and cancer research institutions are fueling an increase in early-phase trial launches. These collaborations often target niche cancers or rare tumors, which begin with Phase I trials to establish safety parameters.

In February 2024, a USD 500,000 grant from the Alliance for Cancer Gene Therapy (ACGT) has been awarded to Dr. E. Antonio Chiocca of Brigham and Women’s Hospital to advance a groundbreaking oncolytic virus therapy for glioblastoma. The award supports preclinical efforts to refine modified viruses that attack brain-tumor cells and activate anti-tumor immune responses. Glioblastoma, a lethal brain cancer affecting roughly 15,000 U.S. adults annually with average survival around eight months, has shown promising results in phase I trials led by Dr. Chiocca. With this support, he plans to optimize viral delivery and immunogenicity ahead of future clinical tests.

Oncolytic Virus Therapy Market Insights, By Distribution Channel

Hospital Pharmacies Dominates the Overall Market

In terms of distribution channel, the hospital pharmacies segment is expected to contribute the greatest share of the market in 2025 due to specialized handling and storage. Oncolytic viruses are biologic agents that must be stored, prepared, and administered under strict sterile and temperature-controlled conditions. Hospital pharmacies are equipped with the infrastructure and trained personnel needed to manage such biologics safely.

Moreover, most oncolytic virus therapies such as Talimogene laherparepvec (T-VEC) for melanoma are administered intratumorally or intravenously, procedures typically performed in hospitals or specialized oncology centers, not retail or online settings.

Additionally, oncolytic therapies may cause immune responses, including fever or inflammation, they require close monitoring for adverse effects. Hospitals provide immediate medical support and lab services that are essential for patient safety during treatment.

In April 2025, Chinese oncology centers reported progress in clinical trials using a modified Newcastle disease virus for advanced tumors, administered intravenously in hospital settings with careful inpatient monitoring. The trial involved 23 patients, with most experiencing measurable tumor shrinkage and halted progression during the hospital-administered treatment phase.

Regional Insights

To learn more about this report, Download Free Sample

North America Oncolytic Virus Therapy Market Analysis & Trends

North America, holding a share of 33.50% in 2025, is expected to dominate the global oncolytic virus therapy market. The region boasts advanced research infrastructure, academic-industry partnerships, and progressive regulatory support—factors fueling innovation and real-world implementation.

For instance, in March 2024, the U.S. Food and Drug Administration granted Fast Track designation to ImmVira’s HSV-based therapy MVR‑T3011, developed for recurrent or metastatic head and neck cancer following resistance to standard treatments. This milestone underscores the speed and seriousness with which regulatory bodies are treating oncolytic virus candidates in North America.

In addition, Genelux’s Olvi‑Vec, a vaccinia virus therapy targeting platinum-resistant ovarian cancer, also secured Fast Track status in late 2023, with Phase III trials underway to potentially broaden its use to other solid tumors. And the Moffitt Cancer Center initiated a clinical trial of MEM‑288 combined with the immunotherapy Opdivo for progressed non–small cell lung cancer patients, showcasing the growing integration of oncolytic platforms in hospital research settings.

These regulatory endorsements and high-profile trial launches reflect both the oncolytic virus therapy market and North America’s position as a global innovation hub, powered by clinical capabilities, funding, and forward-looking frameworks that continue to drive the field forward.

Asia Pacific Oncolytic Virus Therapy Market Analysis & Trends

The Asia Pacific region, holding a share of 16.8% in 2025, is expected to exhibit the fastest growth in the global oncolytic virus therapy market. Asia Pacific is rapidly advancing, particularly in countries like Japan, China, South Korea, due to the growing focused research, supportive regulatory frameworks, and growing drug approvals. In China, over 60 clinical trials are underway exploring oncolytic viruses, which are heralded by scientists as a potential “next frontier” for affordable cancer care, costing as little as USD 140 per dose in some trials, with early evidence of tumor regression.

Meanwhile, Japan pioneered regulatory progress: in early 2025, the health ministry approved Teserpaturev (G47Δ), a genetically engineered herpesvirus for malignant glioma, achieving a one-year survival rate of 92.3% and showcasing hospital-based virotherapy integration. This landmark approval also reflects Japan’s conditional & fast-track regulatory pathways that accelerate access to novel biologics.

Additionally, countries like South Korea are fostering collaborations between biotech firms and academic institutions for next-generation cancer solutions, positioning the region as a hub for immuno-oncology innovation. This is further proliferating the oncolytic virus therapy market revenue.

Oncolytic Virus Therapy Market Outlook Country-Wise

The U.S. Oncolytic Virus Therapy Market Trends

The United States Acquires the prominent oncolytic virus therapy market share, backed by strong biotech investment, advanced clinical research, and regulatory support. It was the first to approve an oncolytic virus therapy which is Talimogene laherparepvec (T-VEC) for melanoma setting the stage for innovation. The U.S. continues to drive early-phase trials targeting solid tumors, melanoma, and pancreatic cancer, with active participation from biotech firms and academic centers he nation’s well-established regulatory pathways and active funding environment continue to encourage rapid development and commercialization of these advanced therapies, making the U.S. a central hub in the evolving global landscape of oncolytic virotherapy.

China Oncolytic Virus Therapy Market Trends

China is becoming a key player in oncolytic virus therapy due to its large patient base, cost-effective trials, and strong government support. In September 2024, Virogin Biotech’s VG161, an HSV-1–based therapy, received Breakthrough Therapy Designation from China’s CDE for liver cancer—the country’s first oncolytic virus to do so. In May 2025, VRT106, derived from hepatitis A virus, began first-in-human trials for solid tumors. With over 60 active clinical studies, China is advancing rapidly in the oncolytic virus therapy market through innovation and regulatory backing.

Market Report Scope

Oncolytic Virus Therapy Market Drivers

• Advancements in Viral Engineering: Advancements in viral engineering are allowing for more precise and targeted oncolytic virus therapies, which is significantly contributing to the growth of the global oncolytic virus therapy market. Scientists are learning to genetically modify viruses to better detect and destroy cancer cells while avoiding healthy tissue. This allows the viruses to spread within the tumor and induce cancer cell death more effectively. For example, researchers have modified the herpes simplex virus to insert genetic sequences that program the virus to selectively replicate inside cancers. In preclinical research, this modified herpes virus showed highly targeted cytotoxicity against various cancers, like melanoma, without toxic effects in normal cells.
• Need for Innovative Cancer Treatments: There is a significant unmet need for effective and targeted cancer treatments. Conventional therapies such as chemotherapy and radiation can have limitations and adverse side effects. Oncolytic virus therapy offers a novel and potentially more targeted approach to cancer treatment, addressing the need for innovative and personalized therapies.

Oncolytic Virus Therapy Market Opportunities

• Combination Therapies: Oncolytic virus therapy can be combined with other treatment modalities such as chemotherapy, immunotherapy, or targeted therapies to enhance treatment outcomes. The synergistic effects of combining oncolytic viruses with other therapies have shown promise in preclinical and clinical studies. Exploring and optimizing combination therapies can lead to improved patient responses and better treatment outcomes.
• Personalized Medicine: Oncolytic virus therapy has the potential to be tailored to individual patients based on their specific cancer characteristics. The ability to customize the oncolytic viruses to target specific genetic alterations or biomarkers in tumors can enhance treatment efficacy and minimize off-target effects. Personalized medicine approaches offer opportunities for more precise and effective cancer treatment.

Oncolytic Virus Therapy Market Trends

• Advancements in Virotherapy Platforms: Advancements in virotherapy platforms are having a significant influence on the global oncolytic virus therapy market. Researchers are developing newer platforms that can more effectively deliver engineered viruses to tumor cells while avoiding healthy tissues. Certain novel platforms enable the precise delivery of oncolytic viruses by combining them with ligands that bind to receptors that are overexpressed in cancerous cells. This enhances the specificity and efficacy of virus therapy. Others are engineering viral particles with enhanced transduction abilities, enabling them to more easily enter tumor cells. For example, certain viruses are now being equipped with mutations that help them evade detection by the immune system, allowing them to replicate for longer within the body. Some groups are also working on multimodal platforms where oncolytic viruses can be combined with immunotherapy or chemotherapeutics to produce enhanced anti-tumor responses. The development of armed oncolytic viruses that can locally produce therapeutic proteins is another area witnessing innovations.
• Targeted Delivery Systems: Efforts to enhance tumor-specific targeting and reduce off-target effects in oncolytic virus therapy are gaining significant attention in oncolytic virus therapy market research. Scientists have developed innovative delivery systems such as nanocapsules that allow intravenous administration while crossing biological barriers. For example, a 2025 study introduced a nanocapsule encapsulating a recombinant EV-A71 virus variant, enabling the virus to cross the blood–brain barrier and selectively release in glioma tissue, dramatically improving tumor targeting and survival in mouse models. Additionally, researchers engineered a herpes simplex virus-1 to express CD47-blocking nanobodies directly on its surface, enhancing recognition by tumor-associated macrophages and avoiding systemic toxicity. These approaches—attaching ligands or antibodies to the virus surface or using nanoparticle coatings—are advancing delivery precision and safety, reinforcing the demand for targeted delivery technologies in the evolving oncolytic virus therapy landscape.

Analyst Opinion (Expert Opinion)

Oncolytic virus therapy market value stands at the frontier of precision oncology, not merely as an experimental adjunct, but increasingly as a transformative modality capable of reshaping standard cancer treatment protocols. In my professional assessment, the promise of oncolytic viruses lies not in their cytolytic capabilities alone, but in their profound immunomodulatory potential, an aspect that traditional chemotherapeutic and targeted agents have repeatedly failed to optimize in refractory malignancies.

Clinical data from recent trials underscores this shift. The Phase III trial of Talimogene laherparepvec (T-VEC) in unresectable melanoma demonstrated a durable response rate of 16.3%, a stark improvement compared to the 2.1% in the control arm. More importantly, T-VEC was observed to convert “cold” tumors into “hot” ones inducing an immune-permissive microenvironment marked by increased CD8+ T cell infiltration and PD-L1 expression. This characteristic alone opens substantial therapeutic value, especially when used in combination with checkpoint inhibitors.

Also, synergistic activity with immune checkpoint blockade is where the next-generation oncolytics are making definitive inroads. A Phase Ib study evaluating the combination of DNX-2401, an oncolytic adenovirus, with pembrolizumab in recurrent glioblastoma showed a 12-month overall survival rate of 52.7%, substantially higher than historical controls in this aggressive setting. These data suggest that oncolytic viruses are not simply direct tumoricidal agents—they are primers of systemic antitumor immunity.

Still, the platform faces two critical bottlenecks: delivery and selectivity. While intratumoral injection has shown promise, systemic delivery remains a challenge due to neutralizing antibodies and hepatic sequestration. However, innovations such as viral cloaking techniques, tumor-specific promoters, and engineered cytokine expression (e.g., GM-CSF, IL-12) are gradually mitigating these barriers. The recently launched LOAd703 platform in pancreatic and ovarian cancers is a case in point—leveraging a replication-competent adenovirus engineered with both immune-stimulatory and targeting genes.

Recent Developments

• In February 2025, Biotech firm UroGen Pharma acquired ICVB‑1042, a next-generation oncolytic virus, from IconOVir Bio as part of its long-term growth strategy. Designed to selectively destroy cancer cells while stimulating immune responses, ICVB‑1042 enhances UroGen’s bladder cancer pipeline via local administration.
• In May 2024, Moffitt Cancer Center, in collaboration with Duke Cancer Institute, initiated a first-in-human trial combining oncolytic virus MEM‑288 with the PD‑1 inhibitor nivolumab for patients with late-stage non–small-cell lung cancer (NSCLC) whose disease progressed after immunotherapy. MEM‑288, an engineered adenovirus expressing IFNβ and a membrane-stable CD40 ligand (MEM40), has demonstrated safety, tumor reduction, and enhanced T‑cell activity in phase 1a.
• In November 2023, the U.S. Food and Drug Administration granted Fast Track designation to Olvi‑Vec (olvimulogene nanivacirepvec), Genelux’s oncolytic vaccinia virus investigational therapy, targeting platinum-resistant or -refractory ovarian cancer. The designation, supported by positive phase 2 VIRO‑15 data, aims to expedite development and review. Olvi‑Vec is currently in a phase 3 OnPrime/GOG‑3076 trial, combining intraperitoneal viral infusion with chemotherapy and bevacizumab.

Market Segmentation

• By Product Type
  • Herpes simplex virus
  • Adenovirus
  • Vaccinia virus
  • Reovirus
  • Measles virus
  • Others (Newcastle disease virus, Vesicular stomatitis virus)
• By Application
  • Melanoma
  • Breast cancer
  • Head and neck cancer
  • Bladder Cancer
  • Prostate Cancer
  • Lung Cancer
  • Others (Colorectal Cancer, and among Others)
• By Development Stage
  • Commercial
  • Pipeline Phase
    • Pre-clinical
    • Phase I
    • Phase II
    • Phase III
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Top Companies in Oncolytic Virus Therapy Market
  • Amgen Inc.
  • Merck & Co., Inc.
  • Oncolytics Biotech Inc.
  • Circio Holding ASA
  • Akamis Bio
  • Vyriad, Inc.
  • SillaJen Biotherapeutics
  • Cold Genesys Inc.
  • Sorrento Therapeutics, Inc.
  • Takara Bio Inc.
  • Replimune Group Inc.
  • Genelux Corporation
  • Synthetic Biologics, Inc.
  • Lokon Pharma AB
  • Elicera Therapeutics

Sources

Primary Research Interviews from the following stakeholders

Stakeholders

• Interviews with clinical oncologists, virologists, biotech R&D heads, manufacturing leads, regulatory affairs specialists, hospital procurement managers, and academic researchers across key oncology research hubs globally.

Databases

• ClinicalTrials.gov – Oncolytic Virus Trials Registry
• World Health Organization – Global Health Observatory Data
• U.S. FDA – Approved Biologics and IND Listings
• European Medicines Agency (EMA) – Advanced Therapies Reports
• Japan Pharmaceuticals and Medical Devices Agency (PMDA) – Cell & Gene Therapy Data
• Central Drugs Standard Control Organization (India) – Biotech Approvals
• Global Cancer Observatory (GLOBOCAN)
• World Bank – Healthcare Expenditure and R&D Investment Statistics
• OECD – Health Data Sets

Scientific Journals

• Molecular Therapy – Oncolytics
• Journal of Immunotherapy for Cancer
• Cancer Gene Therapy
• Nature Reviews Drug Discovery
• OncoImmunology
• Human Gene Therapy
• Frontiers in Oncology – Cancer Immunotherapy Section
• Journal of Clinical Oncology
• The Lancet Oncology

Magazines & Trade Publications

• GEN (Genetic Engineering & Biotechnology News)
• Nature Biotechnology News
• The Scientist – Immunotherapy & Virology Coverage
• BioPharma Dive
• Biotechnology Focus
• Pharma Technology Focus
• Drug Development & Delivery
• Cell & Gene

Newspapers & General Media

• The New York Times – Health & Science
• The Guardian – Biotech & Medicine
• The Economic Times – Biotech & Pharma
• Financial Times – Healthcare Innovation Reports
• Nikkei Asia – Biopharmaceutical Developments
• The Hindu Business Line – Healthcare & R&D

Associations & Agencies

• American Society of Clinical Oncology (ASCO)
• American Association for Cancer Research (AACR)
• International Society for Cell & Gene Therapy (ISCT)
• Alliance for Regenerative Medicine (ARM)
• Cancer Research UK
• Indian Council of Medical Research (ICMR)
• European Society for Medical Oncology (ESMO)
• Department of Biotechnology (DBT), India
• Japan Agency for Medical Research and Development (AMED)
• U.S. National Cancer Institute (NCI)

Public Domain Sources

• National Institutes of Health (NIH), U.S.
• European Commission – Advanced Therapies Unit
• Central Drugs Standard Control Organization (CDSCO), India
• Health Canada – Biologics and Genetic Therapies Directorate
• Ministry of Health, Labour and Welfare (Japan)
• NITI Aayog – Health and Biotechnology Sector Reports
• India Biotechnology Regulations Review Task Force
• Global Viral Vector & Cell Therapy GMP Site Registry
• U.S. Library of Medicine – Virology & Oncotherapy Archives

Proprietary Elements

• CMI Data Analytics Tool, and Proprietary CMI Existing Repository of information for last 8 years

*Definition: Oncolytic virus therapy is a cancer treatment approach that utilizes modified viruses to selectively target and destroy cancer cells while sparing healthy cells. These viruses are designed to replicate within tumor cells, leading to their destruction. Oncolytic virus therapy shows promise for various cancer types and aims to provide a more targeted and effective treatment option for patients.